Exposure to infections in early life is considered a risk-factor for developing schizophrenia. Recently we reported that a neonatal CNS infection with influenza A virus in mice resulted in a transient induction of the brain kynurenine pathway, and subsequent behavioral disturbances in immune-deficient adult mice. The aim of the present study was to investigate a potential role in this regard of kynurenic acid (KYNA), an endogenous antagonist at the glycine site of the N-methyl-D-aspartic acid (NMDA) receptor and at the cholinergic a7 nicotinic receptor. C57BL/6 mice were injected i.p. with neurotropic influenza A/WSN/33 virus (2400 plaque-forming units) at postnatal day (P) 3 or with L-kynurenine (2 Â 200 mg/kg/day) at P7-16. In mice neonatally treated with L-kynurenine prepulse inhibition of the acoustic startle, anxiety, and learning and memory were also assessed. Neonatally infected mice showed enhanced sensitivity to damphetamine-induced (5 mg/kg i.p.) increase in locomotor activity as adults. Neonatally L-kynurenine treated mice showed enhanced sensitivity to d-amphetamine-induced (5 mg/kg i.p.) increase in locomotor activity as well as mild impairments in prepulse inhibition and memory. Also, d-amphetamine tended to potentiate dopamine release in the striatum in kynurenine-treated mice. These long-lasting behavioral and neurochemical alterations suggest that the kynurenine pathway can link early-life infection with the development of neuropsychiatric disturbances in adulthood.
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Introduction
Schizophrenia is a mental disorder, usually emerging in adolescence or early adulthood (Andreasen, 1995) and is characterized by a large diversity of positive and negative symptoms as well as cognitive deficits. Aberrations in brain dopamine (DA) neurotransmission as part of the pathophysiology has for long been the predominant biological hypothesis of schizophrenia (Carlsson and Lindqvist, 1963; Carlsson and Carlsson, 2006) . The DA hypothesis arises from the finding of amelioration in positive symptoms following blockade of DA D 2 -receptors, as well as from observations of psychosis following frequent abuse of the indirect DA agonist d-amphetamine (Angrist and Gershon, 1970; Cruickshank and Dyer, 2009; Griffith et al., 1972) . Further supporting the DA hypothesis, brain imaging studies reveal an enhanced DA release following administration of d-amphetamine in patients with schizophrenia (Abi-Dargham et al., 1998; Breier et al., 1997; Laruelle et al., 1996) . Research during the last decade however, proposes that DA only plays an intermediary role in the pathophysiology and that deficits in brain glutamatergic systems are of major importance for the disease (Carlsson et al., 2001; Javitt, 2004; Jentsch and Roth, 1999) . For example, administration of Nmethyl-D-aspartic acid (NMDA) receptor antagonists (e.g. phencyclidine and ketamine) evokes behavior similar to schizophrenia symptoms in healthy individuals, and exacerbates symptoms in patients with schizophrenia (Adler et al., 1999; Javitt and Zukin, 1991; Luby et al., 1959) . Providing strong support for a dysfunction of glutamatergic transmission in schizophrenia, the concentration of kynurenic acid (KYNA) is elevated in the cerebrospinal fluid (CSF) and in post mortem brain of patients with schizophrenia (Erhardt et al., 2001a; Linderholm et al., 2012; Nilsson et al., 2005; Sathyasaikumar et al., 2011; Schwarcz et al., 2001) . KYNA is a tryptophan metabolite, synthesized in astrocytes via the kynurenine pathway. At nanomolar concentrations, KYNA antagonizes the glycine-site of the NMDA receptor as well as the cholinergic a7 
